Recent Updates
Recently added Catalysts

IPH2101 combined to lenalidomide

Phase 1

Patients With Multiple Myeloma Experiencing a | Small molecule | Oncology |Innate Pharma S.A.|Last Updated: Feb 28, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment15

FDA Designations

No designations recorded

Clinical trial landscape

IPH2101 combined to lenalidomide · 1 trial · 2 indications

Phase 1 1
NCT01217203Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second RelapsePatients With Multiple Myeloma Experiencing a
COMPLETED15 Analytics
PHASE1COMPLETED
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Patients With Multiple Myeloma Experiencing a
NCT0121720315
Unlock trial analytics

Study Endpoints

Primary Endpoints

number of patients with Dose Limiting Toxicity (DLT) at each dose level
1 year

safety of IPH2101 combined with lenalidomide at different dose levels.

Secondary Endpoints

To assess response rate of the combination
1 year
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
IPH2101 and lenalinomideEXPERIMENTAL -

Interventions

NameTypeDescription
IPH2101 combined to lenalidomideDRUGDose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: 1. Signed informed consent obtained before any trial-related activities 2. Progressive disease or relapse of multiple myeloma (according to the IMWG definition) after one or two prior therapeutic treatments or regimens for multiple myeloma that achieved a response duration of at...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about IPH2101 combined to lenalidomide

What is IPH2101 combined with lenalidomide used for?

IPH2101 combined with lenalidomide is an investigational combination therapy being studied for the treatment of patients with multiple myeloma who are experiencing a first or second relapse. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.

Who is developing IPH2101 combined with lenalidomide?

IPH2101 combined with lenalidomide is being developed by Innate Pharma S.A., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol IPHA.

What phase is IPH2101 combined with lenalidomide in?

IPH2101 combined with lenalidomide is in Phase 1 clinical development. The combination is being evaluated in an early-stage trial to assess its safety, anti-tumor activity, and pharmacology in patients with multiple myeloma.

What clinical trials is IPH2101 combined with lenalidomide in?

IPH2101 combined with lenalidomide has been studied in one completed clinical trial, identified as NCT01217203. This Phase 1 study enrolled 15 participants in the United States and evaluated the combination in patients with multiple myeloma experiencing a first or second relapse.

Is IPH2101 combined with lenalidomide the same as IPH2101 alone?

IPH2101 combined with lenalidomide is a combination therapy that includes IPH2101 and the drug lenalidomide. It is distinct from IPH2101 used as a single agent, as the combination is specifically being studied for its potential additive effects in multiple myeloma.